James Wynn Jacobs, MD | |
1436 Gunter Ave, Guntersville, AL 35976-1846 | |
(256) 582-1211 | |
(256) 582-2522 |
Full Name | James Wynn Jacobs |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Location | 1436 Gunter Ave, Guntersville, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902914708 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | AL 13234 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
James Wynn Jacobs, MD 1436 Gunter Ave, Guntersville, AL 35976-1846 Ph: (256) 582-1211 | James Wynn Jacobs, MD 1436 Gunter Ave, Guntersville, AL 35976-1846 Ph: (256) 582-1211 |
News Archive
A new study reveals that children who spend two hours or more in front of a screen (TV, computer, videogames etc.) have over 2.5 fold increase in their odds of having high blood pressure (BP). These odds are increased further by overweight and obesity.
Cancer and memory loss are baby boomers' biggest health fears. Given their weight, maybe heart disease and diabetes should be. Boomers are more obese than other generations, a new poll finds, setting them up for unhealthy senior years.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended June 30, 2010 (2Q10) of $2.00, above management's guidance of $1.65 to $1.70. The 2Q10 results compared to EPS of $1.67 for the quarter ended June 30, 2009 (2Q09). For the six months ended June 30, 2010 (1H10) the company reported $3.52 in EPS compared to $2.89 for the six months ended June 30, 2009 (1H09).
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute, may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and aromatase inhibitors.
› Verified 5 days ago